Medical

According to ReCode Therapeutics, studies of its nebulized lipid nanoparticle DNAI1 mRNA therapy for the treatment of primary ciliary dyskinesia in non-human primates demonstrated that a single dose of the mRNA could be delivered successfully for good distribution in the lungs. Along with the in vivo studies, tests in human and mouse cell models confirmed that DNAI1 … [Read more...] about Positive preclinical results for ReCode Therapeutics’ inhaled mRNA therapy for primary ciliary dyskinesia

 Satsuma Pharmaceuticals has initiated the SUMMIT Phase 3 trial of its STS101 dihydroergotamine (DHE) nasal powder for the treatment of migraine, the company said. A previous Phase 3 trial of STS101 called EMERGE failed to meet its primary endpoints. Topline data from the SUMMIT trial are expected in the second half of 2022. The SUMMIT trial is expected to enroll … [Read more...] about Satsuma initiates new Phase 3 trial of STS101 intranasal DHE powder for migraine

Augmenta Bioworks and TFF Pharmaceuticals have announced that in vitro testing of their AUG-3387 dry powder monoclonal antibody has demonstrated that the mAb neutralizes the SARS-CoV-2 Delta variant, the highly transmissible strain that is currently dominant in numerous countries. In vitro tests had already demonstrated that the mAb could be effective against other … [Read more...] about In vitro tests show Augmenta/TFF dry powder mAb neutralizes SARS-C0V-2 Delta variant

Results from a Phase 1 trial of an inhaled version of CanSino Biologic's Ad5-nCoV vaccine against COVID-19 have been published online in The Lancet Infectious Diseases. The study enrolled 130 healthy volunteers who got either intramuscular Ad5-nCoV, two doses of aerosolized vaccine, or IM vaccine with an aerosolized booster and found that the nebulized vaccine was … [Read more...] about Positive results for Phase 1 trial of CanSinoBio inhaled COVID-19 vaccine

Preclinical studies by researchers from the LKS Faculty of Medicine at The University of Hong Kong have demonstrated that a dry powder formulation of tamibarotene delivered to the lungs of hamster and mice has broad activity against respiratory viruses, including SARS-CoV-2, MERS-CoV, and influenza A H1N1. Results from the studies were published in Advanced … [Read more...] about Inhaled dry powder tamibarotene effective against respiratory viruses in preclinical studies

Sorrento Therapeutics has initiated a Phase 2 trial of its CoviDrops intranasal neutralizing antibody in COVID-19 patients in the UK, the company said. The trial is expected to enroll 350 COVID-19 patients who have mild symptoms or are asymptomatic who will get either 10 mg or 20 mg of CoviDrops via nasal instillation or placebo. Treatment and assessment will take … [Read more...] about Sorrento initiates Phase 2 trial of its intranasal neutralizing antibody against COVID-19

Meissa Vaccines said that a SARS-CoV-2 challenge test of its MV-014-212 intranasal live attenuated vaccine candidate in non-human primates demonstrated similar efficacy for a single dose compared to currently available vaccines, and the intranasal vaccine stimulated both mucosal and systemic antibodies. According to the company, the vaccine generated antibodies able … [Read more...] about Meissa announces results of preclinical testing of its intranasal COVID-19 vaccine, Phase 1 trial update

AIM ImmunoTech has announced a planned Phase 2a human challenge trial of intranasal Ampligen rintatolimod against human rhinovirus and influenza. The company suggested that "Success against these common viruses could also indicate that an Ampligen prophylaxis could help blunt the spread of infection from lethal coronaviruses, as well as other serious viruses." The … [Read more...] about AIM ImmunoTech announces planned human challenge trial of intranasal Ampligen against rhinovirus and flu